Business
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE)
About this update from Omada Health, Inc.
[{"type":"text","content":"Results suggest sustained, long-term impact of Omada’s program on weight loss and longer medication persistence\nSAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada’s behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associated with greater weight loss.² Those who stop GLP-1s tend to regain the weight they lost³ on the medication. Omada’s analyses demonstrated the clinical benefit of its wraparound lifestyle program on members at various stages of GLP-1 usage. Omada Increased GLP-1 Medication Persistence and Weight LossThe first analysis examined GLP-1 persistence rates of 1,124 Omada members enrolled in Omada’s Enhanced GLP-1 Care Track, which provides tailored support to members on their GLP-1 journey. The analysis evaluated Omada members at 12 and 24 weeks in the program, examining how factors such as program engagement impacted members’ medication persistence. While real-world evidence has previously found lower GLP-1 persistence rates⁴ compared to clinical trials,⁵ Omada’s analysis demonstrated that support via Omada’s program supported enhanced persistence commensurate with increased engagement; 84% of participants stayed on their medication for 24 weeks and lost more weight than those who stopped earlier (12.1% vs. 7.4%). It also found that for every 10 additional engagements per week in the initial 12 weeks, the odds of medication persistence were 54% higher. “These findings underscore a critical insight in the evolving landscape of obesity treatment. While GLP-1s are powerful tools, our research demonstrates that lifestyle support programs, like Omada, can enhance their effectiveness,” said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. Omada Members Maintained Sustained Weight Lost 12 months Post-Discont...